Sutro Biopharma (STRO) Depreciation & Amortization (CF) (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $1.6 million in Q4 2025.

• For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 12.22% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $7.3 million (up 1.72% YoY), and the FY2025 full-year result was $7.3 million, up 1.72% from the prior year.
• Depreciation & Amortization (CF) fell to $1.6 million in Q4 2025, from $1.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.9 million in Q1 2025 to a low of $1.1 million in Q3 2021.
• A 5-year average of $1.6 million and a median of $1.7 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) grew 28.62% in 2022 and declined 12.22% in 2025, its largest moves.
• Tracing STRO's Depreciation & Amortization (CF) over 5 years: stood at $1.3 million in 2021, then gained by 21.01% to $1.5 million in 2022, then increased by 11.51% to $1.7 million in 2023, then climbed by 7.87% to $1.8 million in 2024, then decreased by 12.22% to $1.6 million in 2025.
• Business Quant data shows STRO's Depreciation & Amortization (CF) at $1.6 million in Q4 2025, $1.9 million in Q3 2025, and $1.9 million in Q2 2025.